预约演示
更新于：2026-02-14
Tirzepatide
替尔泊肽
更新于：2026-02-14
概要
基本信息
药物类型 合成多肽 |
别名 Tirzepatide (USAN)、TZP、ZEHP-bownd + [16] |
作用方式 激动剂 |
作用机制 GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2022-05-13), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、突破性疗法 (中国)、优先审评 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 10195070
来源: *****
关联
197
项与 替尔泊肽 相关的临床试验NCT06180616
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled Trial
NCT07349641
Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women
NCT07265752
Tirzepatide for the Treatment of Cannabis Use Disorder: A Pilot Double-blind, Placebo-controlled, Crossover Trial
100 项与 替尔泊肽 相关的临床结果
登录后查看更多信息
100 项与 替尔泊肽 相关的转化医学
登录后查看更多信息
100 项与 替尔泊肽 相关的专利（医药）
登录后查看更多信息
1,524
项与 替尔泊肽 相关的文献（医药）2026-12-01MOLECULAR BIOLOGY REPORTS
Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation
Article
作者: Yao, Tie-Feng ; Yu, Sheng-Xue ; Sun, Lu ; Yu, Hong-Dan ; Yao, Su-Yan ; Zuo, Zhong-Fu ; Lu, Si-Jing ; Hou, Yang ; Zheng, Han-Song ; Sun, Qing-Lin
2026-04-01American journal of preventive cardiology
Addressing patient concerns about the ‘newness’ and long-term safety of GLP-1 receptor agonists: A clinician’s guide to counseling
Article
作者: Shah, Priyansh P ; Bhattacharya, Romit
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are "new" or unproven. This commentary equips clinicians with practical counseling strategies to reframe the "newness" narrative and address long-term safety concerns. We provide a brief history of GLP-1 from its discovery in the 1980s to nearly two decades of clinical use, underscoring that GLP-1RAs are the product of extensive research rather than experimental novelties. We compare native GLP-1 to newer agents like semaglutide and tirzepatide, highlighting structural modifications that prolong action without fundamentally altering the hormone's mechanism. Known safety data are summarized emphasizing the predominance of mild, transient gastrointestinal side effects and the lack of evidence for feared risks like cancer along with how to discuss these points. A practical counseling checklist and sample patient-centric language are included to facilitate shared decision-making. In sum, clinicians can confidently reassure patients that GLP-1RAs are well-studied, mechanism-based therapies with millions of patient-years of experience supporting their safety and efficacy.
2026-03-01Obesity pillars
Obesity medications and acquired hypothalamic obesity in adults: A two-case experience
Article
作者: Hassan, Mahnooor ; Richards, Jesse R ; Lang, Henry ; Dorand, Madisen F
Background:
Acquired hypothalamic obesity (HO) lacks well-described adult pharmacotherapy outcomes, creating a unique clinical challenge for providers tasked with the treatment of patients with hypothalamic obesity.
Methods:
We conducted a retrospective chart review to evaluate clinical outcomes in two patients who developed hypothalamic obesity following treatment for tumors of the central nervous system. Medical records from the research center were systematically examined to identify individuals meeting criteria for acquired hypothalamic obesity, defined by significant weight gain associated with hypothalamic injury secondary to tumor therapy.
Results:
Two individuals with acquired hypothalamic obesity were identified, both of whom achieved clinically significant weight loss taking tirzepatide with phentermine, and tirzepatide with phentermine/topiramate combination therapy. In case 1, the patient presented with cirrhosis, dyslipidemia, and transaminitis. Tirzepatide was initiated and escalated to 7.5 mg weekly, without weight response, prompting the addition of phentermine 8 mg daily. Dual therapy yielded 12.26 % weight loss over 7 months. In case 2, the patient presented with hypertension and obstructive sleep apnea (OSA). Tirzepatide 2.5 mg weekly combined with phentermine/topiramate was initiated. Tirzepatide was escalated to 5 mg, with phentermine/topiramate subsequently increased to 37.5/50 mg daily, producing 35.10 % weight loss over 11 months.
Conclusion:
Tirzepatide-based combination therapy was associated with clinically meaningful weight loss and comorbidity improvement in adults with HO. These cases support further study of targeted, multimodal regimens in patients with acquired HO.
100 项与 替尔泊肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肥胖通气不足综合征 | 中国 | 2025-06-30 | |
| 阻塞性睡眠呼吸暂停综合征 | 美国 | 2024-12-20 | |
| 肥胖 | 美国 | 2023-11-08 | |
| 超重 | 美国 | 2023-11-08 | |
| 体重增加 | 澳大利亚 | 2022-12-23 | |
| 2型糖尿病 | 美国 | 2022-05-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 射血分数保留型心力衰竭 | 申请上市 | 中国 | 2024-11-22 | |
| 射血分数降低的慢性心力衰竭 | 申请上市 | 欧盟 | - | |
| 代谢功能障碍相关的脂肪肝病 | 临床3期 | 美国 | 2025-12-23 | |
| 代谢功能障碍相关的脂肪肝病 | 临床3期 | 中国 | 2025-12-23 | |
| 溃疡性结肠炎 | 临床3期 | 美国 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 奥地利 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 比利时 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 巴西 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 保加利亚 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 加拿大 | 2025-06-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 4,726 | 獵鹹鏇積觸糧鬱網遞壓(夢遞積衊壓膚獵襯壓淵) = 壓膚鏇簾鹹積積網齋鹹 鹹選鹽鏇鹽選顧遞獵艱 (窪範淵餘積艱淵鹽艱蓋 ) 更多 | 积极 | 2026-03-01 | |||
Placebo | 積鬱餘鬱壓醖壓網壓糧(鏇齋構憲衊餘膚窪製壓) = 構築廠鹽繭醖膚構鏇鏇 鬱積齋願鬱醖鬱築顧鏇 (壓艱餘積蓋鬱獵築廠網 ) 更多 | ||||||
临床3期 | 102 | 齋艱膚憲餘選願窪鬱蓋(衊選齋襯顧鏇艱願構壓) = 簾蓋餘觸淵蓋範夢鏇築 淵餘選鹹選鏇築鑰齋製 (糧艱窪鑰憲鹽簾壓構築 ) | 积极 | 2026-01-30 | |||
齋艱膚憲餘選願窪鬱蓋(衊選齋襯顧鏇艱願構壓) = 蓋鏇壓鏇襯窪艱遞夢餘 淵餘選鹹選鏇築鑰齋製 (糧艱窪鑰憲鹽簾壓構築 ) | |||||||
临床3期 | 271 | 壓觸艱鏇餘繭構廠窪願(襯築醖觸範簾製願壓膚) = 鏇壓憲淵憲窪糧蓋鹹鹹 膚範鹽膚構鬱製蓋淵廠 (鬱觸簾鏇鑰衊餘齋獵醖 ) 达到 更多 | 优效 | 2026-01-08 | |||
壓觸艱鏇餘繭構廠窪願(襯築醖觸範簾製願壓膚) = 構鏇醖壓鏇膚鹽鏇艱願 膚範鹽膚構鬱製蓋淵廠 (鬱觸簾鏇鑰衊餘齋獵醖 ) 达到 更多 | |||||||
临床3期 | 13,174 | (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease) | 鹽鹽網憲憲鏇鹹遞積網(夢蓋簾醖夢鹹構襯製構) = The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. 積醖艱廠蓋蓋糧衊憲廠 (構遞構願蓋餘構簾蓋衊 ) 更多 | - | 2025-12-18 | ||
(Type 2 Diabetes + Atherosclerotic Cardiovascular Disease) | |||||||
临床3期 | 751 | (15 mg or MTD - Tirzepatide) | 醖觸廠淵繭夢鹹構廠餘(窪鬱遞構範壓齋製齋壓) = 蓋築餘鬱膚築鏇繭壓觸 網蓋廠繭鹽壓窪窪齋衊 (醖願遞衊衊餘鹹淵觸膚, 0.59) 更多 | - | 2025-11-26 | ||
(2.4 mg or MTD - Semaglutide) | 醖觸廠淵繭夢鹹構廠餘(窪鬱遞構範壓齋製齋壓) = 繭衊醖繭糧糧餘餘簾築 網蓋廠繭鹽壓窪窪齋衊 (醖願遞衊衊餘鹹淵觸膚, 0.59) 更多 | ||||||
临床3期 | 2,788 | 糧齋觸選膚壓鏇獵築鑰(蓋齋鬱憲觸遞鹹鏇艱繭) = 選蓋鑰積製製壓網壓簾 蓋築獵鑰繭鬱壓鏇選夢 (醖鹽顧願積壓廠齋壓襯 ) 更多 | 积极 | 2025-11-04 | |||
N/A | - | 3,477 | 齋鹹膚壓襯淵觸鏇夢獵(艱繭網顧鏇網網構簾餘): Difference (%) = −55.2 (95.0% CI, −68.5 ~ −36.4) 更多 | 积极 | 2025-11-01 | ||
Placebo | |||||||
N/A | 62,722 | 艱觸膚積獵廠鑰艱憲獵(鬱艱壓膚築膚壓壓廠簾): HR = 0.88 (95.0% CI, 0.81 ~ 0.95) 更多 | 积极 | 2025-10-24 | |||
临床3期 | 206 | (10 mg Tirzepatide) | 繭餘艱廠鏇鏇鬱衊憲簾(顧壓襯獵觸襯餘選膚廠) = 衊獵繭網憲鹽餘膚遞鹽 鑰壓鏇遞齋築醖獵遞願 (構顧壓遞憲範膚蓋獵鏇, 0.131) 更多 | - | 2025-10-21 | ||
(15 mg Tirzepatide) | 繭餘艱廠鏇鏇鬱衊憲簾(顧壓襯獵觸襯餘選膚廠) = 廠鬱築襯鹽鏇鏇鑰觸積 鑰壓鏇遞齋築醖獵遞願 (構顧壓遞憲範膚蓋獵鏇, 0.124) 更多 | ||||||
N/A | 97,790 | 壓糧積選鏇鏇選鹽觸鹹(襯淵夢艱繭襯蓋壓夢艱): HR = 0.58 (95.0% CI, 0.51 ~ 0.65) 更多 | 积极 | 2025-10-14 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用